TY - JOUR AB - Carbon ion therapy (CIT) is a form of particle therapy, which not only spares normal tissues but may also improve local control of recurrent intracranial tumours. Cerebral radiation necrosis (RN) is one of the most serious adverse reactions of recurrent brain tumours following reirradiation, which may lead to neurological decline or even death. Bevacizumab is an anti‑vascular endothelial growth factor antibody, which has been used to treat symptomatic RN. However, studies on bevacizumab for the treatment of CIT‑induced RN are sparse. The present study described two cases that were successfully treated with bevacizumab for symptomatic RN following CIT for recurrent intracranial malignant tumours. The two recurrent intracranial malignant tumours, a chondrosarcoma in the right cavernous sinus and an anaplastic meningioma in the right frontal lobe, were enrolled in a clinical trial of CIT. Both cases were treated intravenously with bevacizumab when deterioration that appeared to be symptomatic brain RN was observed. Just before CIT, enhanced magnetic resonance imaging (MRI) was performed in each case to confirm tumour recurrence. Both cases exhibited a deterioration in symptoms, as well as on MRI, at 12‑month intervals following CIT. The first case underwent positron emission tomography/computed tomography to confirm no increase in fluorodeoxyglucose uptake in lesion areas. Both cases were diagnosed as having symptomatic brain RN and began intravenous administration of four cycles of 5 mg/kg bevacizumab biweekly. The patients responded well, with rapid and marked improvements on MRI, and in clinical symptoms. No tumour progression was observed 24 months after CIT. In conclusion, bevacizumab was revealed to exert marked effects on symptomatic brain RN following CIT. Notably, cycles of bevacizumab should be administered specifically based on the aim of treating brain necrosis, and long‑term or prophylactic applications are not recommended. AD - Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000, P.R. China The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu 730000, P.R. China AU - Liu,Ruifeng AU - Luo,Hongtao AU - Zhang,Qiuning AU - Sun,Shilong AU - Liu,Zhiqiang AU - Wang,Xiaohu AU - Geng,Yichao AU - Zhao,Xueshan DA - 2022/07/01 DO - 10.3892/mco.2022.2547 IS - 1 JO - Mol Clin Oncol KW - bevacizumab carbon ion therapy recurrent intracranial malignant tumor cerebral radiation necrosis PY - 2022 SN - 2049-9450 2049-9469 SP - 114 ST - Bevacizumab is an effective treatment for symptomatic cerebral necrosis after carbon ion therapy for recurrent intracranial malignant tumours: A case report T2 - Molecular and Clinical Oncology TI - Bevacizumab is an effective treatment for symptomatic cerebral necrosis after carbon ion therapy for recurrent intracranial malignant tumours: A case report UR - https://doi.org/10.3892/mco.2022.2547 VL - 17 ER -